JP2017504601A - 免疫療法のためにマルチインプットシグナル感受性ｔ細胞を操作する方法 - Google Patents

免疫療法のためにマルチインプットシグナル感受性ｔ細胞を操作する方法 Download PDF

Info

Publication number
JP2017504601A
JP2017504601A JP2016541194A JP2016541194A JP2017504601A JP 2017504601 A JP2017504601 A JP 2017504601A JP 2016541194 A JP2016541194 A JP 2016541194A JP 2016541194 A JP2016541194 A JP 2016541194A JP 2017504601 A JP2017504601 A JP 2017504601A
Authority
JP
Japan
Prior art keywords
domain
car
cells
cell
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016541194A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017504601A5 (enExample
Inventor
アレキサンドル ジュイラ
アレキサンドル ジュイラ
クラウディア ベルトナティ
クラウディア ベルトナティ
ジュリアン ヴァルトン
ジュリアン ヴァルトン
フィリップ デュシャトー
フィリップ デュシャトー
ローラン ポワロ
ローラン ポワロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellectis SA
Original Assignee
Cellectis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectis SA filed Critical Cellectis SA
Publication of JP2017504601A publication Critical patent/JP2017504601A/ja
Publication of JP2017504601A5 publication Critical patent/JP2017504601A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2016541194A 2013-12-20 2014-12-19 免疫療法のためにマルチインプットシグナル感受性ｔ細胞を操作する方法 Pending JP2017504601A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201370806 2013-12-20
DKPA201370806 2013-12-20
PCT/EP2014/078876 WO2015092024A2 (en) 2013-12-20 2014-12-19 Method of engineering multi-input signal sensitive t cell for immunotherapy

Publications (2)

Publication Number Publication Date
JP2017504601A true JP2017504601A (ja) 2017-02-09
JP2017504601A5 JP2017504601A5 (enExample) 2018-01-18

Family

ID=49884853

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016541194A Pending JP2017504601A (ja) 2013-12-20 2014-12-19 免疫療法のためにマルチインプットシグナル感受性ｔ細胞を操作する方法

Country Status (6)

Country Link
US (1) US10239948B2 (enExample)
EP (2) EP3083691A2 (enExample)
JP (1) JP2017504601A (enExample)
AU (1) AU2014368383B2 (enExample)
CA (1) CA2934436A1 (enExample)
WO (1) WO2015092024A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020512019A (ja) * 2017-03-31 2020-04-23 セレクティス ソシエテ アノニム ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞
WO2020175366A1 (ja) * 2019-02-25 2020-09-03 国立大学法人東京医科歯科大学 キメラ抗原受容体
JPWO2021131944A1 (enExample) * 2019-12-27 2021-07-01
JP2022520285A (ja) * 2019-02-19 2022-03-29 キングス カレッジ ロンドン 低酸素応答性キメラ抗原受容体
JP2022533806A (ja) * 2018-11-06 2022-07-26 イミュニティーバイオ、インコーポレイテッド キメラ抗原受容体で修飾されたｎｋ－９２細胞
JP2024001096A (ja) * 2018-05-22 2024-01-09 イミュニティーバイオ、インコーポレイテッド ＦｃイプシロンＣＡＲ
US12109238B2 (en) 2018-11-06 2024-10-08 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ723731A (en) 2011-04-08 2020-05-29 Baylor College Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
US9752113B2 (en) 2012-03-15 2017-09-05 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US9745548B2 (en) 2012-03-15 2017-08-29 Flodesign Sonics, Inc. Acoustic perfusion devices
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10689609B2 (en) 2012-03-15 2020-06-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US10322949B2 (en) 2012-03-15 2019-06-18 Flodesign Sonics, Inc. Transducer and reflector configurations for an acoustophoretic device
US10737953B2 (en) 2012-04-20 2020-08-11 Flodesign Sonics, Inc. Acoustophoretic method for use in bioreactors
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
US9745569B2 (en) 2013-09-13 2017-08-29 Flodesign Sonics, Inc. System for generating high concentration factors for low cell density suspensions
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
ES2740903T3 (es) * 2014-03-19 2020-02-07 Cellectis Receptores antigénicos quiméricos específicos de CD123 para inmunoterapia del cáncer
SG11201608393TA (en) 2014-04-10 2016-11-29 Seattle Children S Hospital Dba Seattle Children S Res Inst Transgene genetic tags and methods of use
EP3131927B8 (en) 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
EP3143134B1 (en) 2014-05-15 2020-10-28 National University of Singapore Modified natural killer cells and uses thereof
US9744483B2 (en) 2014-07-02 2017-08-29 Flodesign Sonics, Inc. Large scale acoustic separation device
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
HRP20240357T1 (hr) 2014-12-24 2024-06-07 Autolus Limited Stanica
CA2973529A1 (en) 2015-01-26 2016-08-04 Cellectis Cll1-specific multi-chain chimeric antigen receptor
WO2016126608A1 (en) * 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
IL254817B2 (en) 2015-04-08 2023-12-01 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
KR20180029201A (ko) 2015-05-18 2018-03-20 티씨알2 테라퓨틱스 인크. 융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법
MA42902A (fr) 2015-07-08 2018-05-16 Univ Johns Hopkins Lymphocytes infiltrant la moelle (mil) en tant que source de lymphocytes t pour une thérapie par des récepteurs chimériques d'un antigène (car)
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
PT3331910T (pt) 2015-08-03 2020-03-24 Engmab Sarl Anticorpos monoclonais contra o antigénio de maturação de células b (bcma) humano
US11458167B2 (en) * 2015-08-07 2022-10-04 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
SG10202112024PA (en) 2016-01-11 2021-12-30 Univ Leland Stanford Junior Chimeric proteins and methods of immunotherapy
NZ743983A (en) * 2016-01-11 2025-08-29 Univ Leland Stanford Junior Chimeric proteins and methods of regulating gene expression
DK3405490T3 (da) 2016-01-21 2022-01-10 Pfizer Mono- og bispecifikke antistoffer mod epidermal vækstfaktorreceptor variant iii og cd3 og anvendelser deraf
US10259876B2 (en) * 2016-01-21 2019-04-16 Pfizer Inc. Chimeric antigen receptors targeting epidermal growth factor receptor variant III
EP3202783A1 (en) * 2016-02-02 2017-08-09 Ecole Polytechnique Fédérale de Lausanne (EPFL) Engineered antigen presenting cells and uses thereof
EP3420093B1 (en) * 2016-02-26 2022-11-23 Cellectis Micelle based system nuclease encapsulation for in-vivo gene editing
CN107298715B (zh) * 2016-04-15 2021-05-04 阿思科力(苏州)生物科技有限公司 Slit2D2-嵌合抗原受体及其应用
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
GB201609604D0 (en) * 2016-06-01 2016-07-13 Ucl Business Plc Cell
KR20190019121A (ko) 2016-06-17 2019-02-26 오사카 유니버시티 종양 내 정맥 형성 촉진제
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN108699163B (zh) * 2016-09-28 2021-11-19 阿思科力(苏州)生物科技有限公司 一种多基因重组嵌合抗原受体分子及其应用
IL302917A (en) 2016-10-07 2023-07-01 Tcr2 Therapeutics Inc Compositions and methods for t-cell receptors reprogramming using fusion proteins
CN110494543A (zh) 2016-10-19 2019-11-22 弗洛设计声能学公司 通过声学的亲和细胞提取
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
US11124577B2 (en) 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
CN110291200B (zh) 2016-12-12 2024-05-14 西雅图儿童医院（Dba西雅图儿童研究所） 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体
SG11201908492PA (en) 2017-03-27 2019-10-30 Nat Univ Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
EP3601537A4 (en) 2017-03-27 2021-01-13 National University of Singapore STIMULATING CELL LINES FOR EX VIVO EXPANSION AND ACTIVATION OF NATURAL KILLER CELLS
WO2018193231A1 (en) * 2017-04-18 2018-10-25 Autolus Limited Cell
WO2018213332A1 (en) * 2017-05-17 2018-11-22 Seattle Children's Hospital (dba Seattle Children's Research Institute) Generating mammalian t cell activation inducible synthetic promoters (syn+pro) to improve t cell therapy
JP2020530277A (ja) 2017-06-30 2020-10-22 セレクティスＣｅｌｌｅｃｔｉｓ 反復投与のための細胞免疫療法
GB201711470D0 (en) * 2017-07-17 2017-08-30 Univ Oxford Innovation Ltd Chimeric receptors
EP3662055A1 (en) * 2017-08-02 2020-06-10 Autolus Limited Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
WO2019072824A1 (en) 2017-10-09 2019-04-18 Cellectis IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES
KR20220066413A (ko) 2017-12-14 2022-05-24 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
WO2019118902A2 (en) 2017-12-15 2019-06-20 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inhibiting t cell exhaustion
CN111801348A (zh) 2018-02-09 2020-10-20 新加坡国立大学 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
KR20200138741A (ko) 2018-04-02 2020-12-10 내셔널 유니버시티 오브 싱가포르 면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화
WO2019195586A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
US12090170B2 (en) 2018-04-06 2024-09-17 The Regents Of The University Of California Methods of treating glioblastomas
WO2020028744A1 (en) * 2018-08-02 2020-02-06 Asimov, Inc. Universal chimeric receptors
CA3108710A1 (en) * 2018-08-07 2020-02-13 Purdue Research Foundation Rejuvenation of car t cell
JP7560882B2 (ja) 2018-08-29 2024-10-03 ナショナル ユニヴァーシティー オブ シンガポール 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法
JP7429222B2 (ja) * 2018-08-31 2024-02-07 アンヴェクティ エスアー Ｃａｒの機能を評価する方法
US11542305B2 (en) * 2018-08-31 2023-01-03 California Institute Of Technology Synthetic protein circuits detecting signal transducer activity
WO2020051562A2 (en) 2018-09-07 2020-03-12 Beam Therapeutics Inc. Compositions and methods for improving base editing
AU2019374103A1 (en) 2018-11-01 2021-05-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
JP2022529380A (ja) 2019-04-26 2022-06-21 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル キメラ抗原受容体構築物およびｃａｒ－ｔ細胞におけるそれらの使用
CN114945382A (zh) 2019-11-26 2022-08-26 诺华股份有限公司 Cd19和cd22嵌合抗原受体及其用途
CA3161488A1 (en) * 2019-12-11 2021-06-17 Daniel Getts Therapeutic cell compositions and methods for manufacture and uses thereof
EP4203980A1 (en) * 2020-08-28 2023-07-05 Innovative Cellular Therapeutics Holdings, Ltd. Fusion protein enhancing cell therapy
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CA3232968A1 (en) 2021-10-14 2023-04-20 Jasper Williams Immune cells having co-expressed shrnas and logic gate systems
WO2023070527A1 (zh) * 2021-10-29 2023-05-04 上海鑫湾生物科技有限公司 一种条件控制的可剪接嵌合抗原受体分子及其应用
US20250017960A1 (en) * 2021-11-15 2025-01-16 The Board Of Trustees Of The Leland Stanford Junior University Composition and method of valency controlled receptor systems for cell engineering and therapy
WO2024015383A1 (en) * 2022-07-12 2024-01-18 Northwestern University Engineered hypoxia biosensors and methods of using the same
EP4565262A2 (en) 2022-08-05 2025-06-11 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
EP4573116A2 (en) * 2022-08-15 2025-06-25 The Regents Of The University Of California Multi-chain synthetic receptors for simultaneous ligand-induced transcriptional regulation and membrane-proximal signal transduction
EP4593850A2 (en) 2022-09-30 2025-08-06 The Regents of the University of California Compositions and methods for enhancing adoptive t cell therapeutics
CN119306846A (zh) * 2023-07-14 2025-01-14 广州百吉生物制药有限公司 一种工程化免疫细胞及其制备和应用
WO2025054489A1 (en) * 2023-09-08 2025-03-13 The Regents Of The University Of California Chimeric antigen receptors with card domains
WO2025076422A1 (en) * 2023-10-05 2025-04-10 The Regents Of The University Of California Regulated expression of card11-pik3r3 fusion protein
WO2025084881A1 (ko) * 2023-10-20 2025-04-24 주식회사 이온셀 Ct83 항원에 결합하는 car-t 세포 및 이의 용도

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004524848A (ja) * 2001-03-21 2004-08-19 アイシス イノヴェイション リミテッド アッセイ、方法および手段
JP2008509209A (ja) * 2004-08-09 2008-03-27 キャンサー・リサーチ・テクノロジー・リミテッド αケトグルタレート類および治療薬としてのその使用
JP2009545310A (ja) * 2006-07-31 2009-12-24 ヴァスキュラー バイオジェニックス リミテッド ポリペプチド、および、当該ポリペプチドをコードするポリヌクレオチド、および、虚血に関連する医学的状態の治療におけるそれらの使用
WO2012099973A2 (en) * 2011-01-18 2012-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
WO2013176915A1 (en) * 2012-05-25 2013-11-28 Roman Galetto Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
WO2014153270A1 (en) * 2013-03-16 2014-09-25 Novartis Ag Treatment of cancer using humanized anti-cd19 chimeric antigen receptor
WO2014180306A1 (zh) * 2013-05-08 2014-11-13 上海益杰生物技术有限公司 编码gpc3嵌合抗原受体蛋白的核酸及表达gpc3嵌合抗原受体蛋白的t淋巴细胞
WO2014184143A1 (en) * 2013-05-13 2014-11-20 Cellectis Cd19 specific chimeric antigen receptor and uses thereof
WO2014184744A1 (en) * 2013-05-13 2014-11-20 Cellectis Methods for engineering highly active t cell for immunotherapy
WO2014184741A1 (en) * 2013-05-13 2014-11-20 Cellectis Methods for engineering allogeneic and highly active t cell for immunotheraphy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
WO2006089133A2 (en) * 2005-02-15 2006-08-24 Duke University Anti-cd19 antibodies and uses in oncology
JP2010532764A (ja) * 2007-07-06 2010-10-14 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
PL3006459T3 (pl) * 2008-08-26 2022-01-17 City Of Hope Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA2850411C (en) 2011-09-28 2023-08-15 Era Biotech, S.A. Split inteins and uses thereof
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
CN103483452B (zh) * 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
AU2013312838B2 (en) * 2012-09-04 2018-11-29 Cellectis Multi-chain chimeric antigen receptor and uses thereof
EP2970426B1 (en) * 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EP3925618A1 (en) * 2013-07-29 2021-12-22 2seventy bio, Inc. Multipartite signaling proteins and uses thereof

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004524848A (ja) * 2001-03-21 2004-08-19 アイシス イノヴェイション リミテッド アッセイ、方法および手段
JP2008509209A (ja) * 2004-08-09 2008-03-27 キャンサー・リサーチ・テクノロジー・リミテッド αケトグルタレート類および治療薬としてのその使用
JP2009545310A (ja) * 2006-07-31 2009-12-24 ヴァスキュラー バイオジェニックス リミテッド ポリペプチド、および、当該ポリペプチドをコードするポリヌクレオチド、および、虚血に関連する医学的状態の治療におけるそれらの使用
WO2012099973A2 (en) * 2011-01-18 2012-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
WO2013176915A1 (en) * 2012-05-25 2013-11-28 Roman Galetto Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
WO2013176916A1 (en) * 2012-05-25 2013-11-28 Roman Galetto Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
US20140134142A1 (en) * 2012-05-25 2014-05-15 Cellectis Multi-Chain Chimeric Antigen Receptor and Uses Thereof
WO2014153270A1 (en) * 2013-03-16 2014-09-25 Novartis Ag Treatment of cancer using humanized anti-cd19 chimeric antigen receptor
WO2014180306A1 (zh) * 2013-05-08 2014-11-13 上海益杰生物技术有限公司 编码gpc3嵌合抗原受体蛋白的核酸及表达gpc3嵌合抗原受体蛋白的t淋巴细胞
WO2014184143A1 (en) * 2013-05-13 2014-11-20 Cellectis Cd19 specific chimeric antigen receptor and uses thereof
WO2014184744A1 (en) * 2013-05-13 2014-11-20 Cellectis Methods for engineering highly active t cell for immunotherapy
WO2014184741A1 (en) * 2013-05-13 2014-11-20 Cellectis Methods for engineering allogeneic and highly active t cell for immunotheraphy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANG SONNY O; OLIVARES SIMON; DENIGER DREW C; LEE DEAN A; CHAMPLIN RICHARD E; COOPER LAURENCE J: "CONDITIONAL ACTIVATION OF T CELLS TO SPECIFICALLY TARGET C-MET UNDER HYPOXIA", MOLECULAR THERAPY, vol. VOL:17, NR:SUPPL.1, JPN5017001555, May 2009 (2009-05-01), GB, pages 25 - 26, ISSN: 0004286322 *
ANG SONNY O; OLIVARES SIMON; SHPALL ELIZABETH J; LEE DEAN A; CHAMPLIN RICHARD, ET AL.: "CONDITIONAL T-CELL ACTIVATION FOR TUMOR UNDER HYPOXIA", BLOOD, vol. VOL:112, NR:11, JPN5017001556, November 2008 (2008-11-01), US, pages 1331 - 1332, ISSN: 0004286323 *
PLOS ONE, vol. 8(2), JPN6019029963, 2013, pages 57695 - 1, ISSN: 0004286324 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7634045B2 (ja) 2017-03-31 2025-02-20 セレクティス ソシエテ アノニム ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞
JP2020512019A (ja) * 2017-03-31 2020-04-23 セレクティス ソシエテ アノニム ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞
JP7314115B2 (ja) 2017-03-31 2023-07-25 セレクティス ソシエテ アノニム ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞
JP2023139070A (ja) * 2017-03-31 2023-10-03 セレクティス ソシエテ アノニム ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞
US12435122B2 (en) 2018-05-22 2025-10-07 Immunitybio, Inc. Fc-epsilon CAR
JP7748431B2 (ja) 2018-05-22 2025-10-02 イミュニティーバイオ、インコーポレイテッド ＦｃイプシロンＣＡＲ
JP2024001096A (ja) * 2018-05-22 2024-01-09 イミュニティーバイオ、インコーポレイテッド ＦｃイプシロンＣＡＲ
US12109238B2 (en) 2018-11-06 2024-10-08 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells
JP7739389B2 (ja) 2018-11-06 2025-09-16 イミュニティーバイオ、インコーポレイテッド キメラ抗原受容体で修飾されたｎｋ－９２細胞
JP2022533806A (ja) * 2018-11-06 2022-07-26 イミュニティーバイオ、インコーポレイテッド キメラ抗原受容体で修飾されたｎｋ－９２細胞
JP2024037752A (ja) * 2018-11-06 2024-03-19 イミュニティーバイオ、インコーポレイテッド キメラ抗原受容体で修飾されたｎｋ－９２細胞
JP7536649B2 (ja) 2018-11-06 2024-08-20 イミュニティーバイオ、インコーポレイテッド キメラ抗原受容体で修飾されたｎｋ－９２細胞
JP2022520285A (ja) * 2019-02-19 2022-03-29 キングス カレッジ ロンドン 低酸素応答性キメラ抗原受容体
JP7684692B2 (ja) 2019-02-19 2025-05-28 キングス カレッジ ロンドン 低酸素応答性キメラ抗原受容体
JP7684691B2 (ja) 2019-02-25 2025-05-28 国立大学法人東京科学大学 キメラ抗原受容体
JPWO2020175366A1 (enExample) * 2019-02-25 2020-09-03
WO2020175366A1 (ja) * 2019-02-25 2020-09-03 国立大学法人東京医科歯科大学 キメラ抗原受容体
WO2021131944A1 (ja) * 2019-12-27 2021-07-01 国立大学法人神戸大学 癌遺伝子治療薬
JP7737708B2 (ja) 2019-12-27 2025-09-11 国立大学法人神戸大学 癌遺伝子治療薬
JPWO2021131944A1 (enExample) * 2019-12-27 2021-07-01
US12459984B2 (en) 2019-12-27 2025-11-04 National University Corporation Kobe University Cancer gene therapy drug

Also Published As

Publication number Publication date
WO2015092024A2 (en) 2015-06-25
US20170073423A1 (en) 2017-03-16
AU2014368383A1 (en) 2016-06-30
WO2015092024A3 (en) 2015-08-13
US10239948B2 (en) 2019-03-26
EP3083691A2 (en) 2016-10-26
AU2014368383B2 (en) 2020-01-16
EP3808410A1 (en) 2021-04-21
CA2934436A1 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
US10239948B2 (en) Method of engineering multi-input signal sensitive T cell for immunotherapy
AU2021201967B2 (en) Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy
JP6998917B2 (ja) 免疫療法のために同種異系かつ高活性のｔ細胞を操作するための方法
CN111479921B (zh) 用于以基因方式修饰且扩增淋巴细胞以及调节其活性的方法及组合物
CN110869046B (zh) 通用型抗cd22嵌合抗原受体工程化的免疫细胞
AU2016313082B2 (en) Chimeric antigen receptors with integrated controllable functions
KR102170533B1 (ko) 암 면역요법을 위한 cd33 특이적 키메라 항원 수용체들
EP2893004B1 (en) Multi-chain chimeric antigen receptor and uses thereof
AU2015367317A1 (en) Inhibitory chimeric antigen receptor (iCAR or N-CAR) expressing non-T cell transduction domain
CN115058395A (zh) 嵌合抗原受体(car)、组合物及其使用方法
JP2020519267A (ja) より安全な細胞免疫療法のためのプロテアーゼベースの切り替えキメラ抗原受容体
RU2775453C2 (ru) Сконструированные универсальные иммунные клетки с анти-cd22 химерным антигенным рецептором
HK40071469A (en) Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
Zhu Next Generation Receptors for the Enhanced Control of Cell-based Immunotherapies
HK40001542A (en) Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
HK40001542B (en) Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
HK1208879B (en) Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
HK1212728B (en) Multi-chain chimeric antigen receptor and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200617